がん疼痛緩和のためのマインドフルネス指向の回復強化 (MORE)
マインドフルネス指向の回復強化 (MORE) をがん疼痛緩和に適応: MORE Relief 試験
The purpose of this study is to evaluate whether or not mindfulness-based interventions/MBIs may help reduce chronic pain in participants who have cancer-related chronic pain. MBIs are therapeutic programs that use mindfulness meditation practices to help people focus on the present moment, as well as encourage acceptance of thoughts, emotions, and body sensations. The researchers think that an MBI treatment called Mindfulness-oriented Recovery Enhancement (MORE) may help people who are experiencing cancer-related chronic pain.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- English speaking
- Age ≥ 18 years or older
- A history of cancer with no restrictions placed on type of cancer
- Determined to be either no-evidence of disease or stable oncological disease by referring or study physicians/advanced practice providers
- Having a pain (musculoskeletal, generalized, or neuropathic) rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week
- Having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days
- Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: MORE or WLC
- Ability to attend video-call session and a quiet/private location
Exclusion Criteria:
- Active suicidality or schizophrenia
- Plan to initiate palliative radiation or interventional pain procedure within the next 12 weeks
- Cognitive impairment preventing completing PRO independently or participate in virtual MORE as evaluated by study clinicians
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター：Wait List Control (WLC) Usual Care Procedure
Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers. |
Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers. |
|
実験的：16-hour MORE treatments
Patients in the 16-hour MORE format will receive one 2hrs treatment a week for 8 consecutive weeks (as per study schema: from week 1 to week 8). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
|
実験的：8-hour MORE treatments
Patients in the 8-hour MORE format will receive one 2hrs treatment a week for 4 consecutive weeks (as per study schema: from week 1 to week 4). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
|
実験的：2-hour MORE treatments
Patients in the 2-hour MORE format will receive one 2hrs treatment (as per study schema: in week 1). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of participant enrollment to the study
時間枠：12 months
|
Feasibility of the intervention will be determined by Rate of participant enrollment to the study |
12 months
|
協力者と研究者
捜査官
- 主任研究者：Jun Mao, MD, MSCE、Memorial Sloan Kettering Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 23-082
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。